Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Torrent Makes ‘Cautious’ Comeback With Losartan In US

Executive Summary

Torrent restarts sale of losartan in the US, exercising caution to ensure the API sourced is “impurity free.” Timely resolution of compliance deviations at the firm’s Indian sites is also critical for growth momentum in the US.

You may also be interested in...



As US Slows Down, Torrent Aims For Germany, Brazil

A lack of new launches and price erosion caused a sharp dip in Torrent’s Q3 US revenues, but the company plans to ramp up its presence in Brazil and Germany to build momentum. Meanwhile, the field force in India has been downsized with an aim to defocus on older brands.

As US Slows Down, Torrent Aims For Germany, Brazil

A lack of new launches and price erosion caused a sharp dip in Torrent’s Q3 US revenues, but the company plans to ramp up its presence in Brazil and Germany to build momentum. Meanwhile, the field force in India has been downsized with an aim to defocus on older brands.

US FDA Warns Torrent Over Losartan Process Validation, OOS Invalidation Failures

Warning letter stemming from global nitrosamine investigation raises new concerns about Indian manufacturer.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC125592

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel